MiMedx Group, Inc. cash flow to debt ratio of 328.44% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

MiMedx Group, Inc.'s free cash flow has increased 13.11% from $64.52M last year to $72.97M, signaling increasing performance

MiMedx Group, Inc.'s debt to equity ratio is 0.07, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

MiMedx Group, Inc.'s debt has decreased relative to shareholder equity from 0.13 last year to 0.07 today, signaling strengthened financials

MiMedx Group, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

MiMedx Group, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

MiMedx Group, Inc.'s profit margin has decreased (-35.17%) in the last year from 12.16% to 7.88%, signaling decreasing performance

MiMedx Group, Inc.'s short-term assets of $277.47M exceed its short-term liabilities of $64.27M

MiMedx Group, Inc.'s return on assets of 9.94% is higher than the 5.00% threshold, indicating efficient asset utilization

MiMedx Group, Inc.'s return on equity of 12.86%, is lower than 15.00%, indicating bad performance

MiMedx Group, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

MiMedx Group, Inc. had positive net income in 3.00 out of 5 years, indicating stable and consistent earnings

MiMedx Group, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

MiMedx Group, Inc. has a free cash flow yield of 12.47%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

MiMedx Group, Inc.'s yearly earnings has increased 14.52% since last year from $42.42M to $48.58M, signaling increasing performance

MiMedx Group, Inc.'s yearly revenue has increased 19.99% since last year from $348.88M to $418.63M, signaling increasing performance

ROIC 10.81% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

MiMedx Group, Inc.'s 3-year revenue CAGR of 16.05% is positive, indicating growing revenue over the past 3 years

MiMedx Group, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

MiMedx Group, Inc. had positive ROE in 3.00 out of 5 years, indicating consistent and reliable returns on equity

MiMedx Group, Inc. has insufficient data to evaluate this check.

MiMedx Group, Inc. has an earnings yield of 5.26%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

MiMedx Group, Inc. is undervalued relative to its fair value price of 4.88 based on EBITDA multiple model

MiMedx Group, Inc. has an EV/EBITDA ratio of 7.74x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

MiMedx Group, Inc. is undervalued relative to its fair value price of 5.85 based on Earnings Fair Value model

MiMedx Group, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

MiMedx Group, Inc. has a price-to-book ratio of 2.40x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

MiMedx Group, Inc. has a price-to-sales ratio of 1.50x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue